Применение мелоксикама (амелотекс®) у больных гонартрозом
https://doi.org/10.14412/1996-7012-2011-665
Аннотация
Литература
1. <div><p>Murphy L., Schwartz T.A., Helmick C.G. et al. Lifetime risk of symptomatic knee osteoarthritis. Arthr Rheum 2008; 59: 1207-13.</p><p>Van Saase J.L., van Romunde L.K., Cats A. et al. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989; 48: 271-80.</p><p>The Acetaminophen Hepatotoxicity Working Group FDA. Recommendations for FDA Interventions to Decrease the Occurrence of Acetaminophen Hepatotoxicity. www.fda.gov/ohrms/dockets/ac/09/brief <http://www.fda.gov/ohrms/dockets/ac/09/brief->ing/2009-4429b1-02-FDA.pdf (2.9.2010).</p><p>Jordan K., Arden N., Doherty M. et al. EULAR Recommendation 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.</p><p>Zhang W., Doherty M., Leeb B.F. et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66(3): 377-88.</p><p>Wegman A., van der Windt D., van Tulder M. et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. J Rheumatol 2004; 31: 344-54.</p><p>Chen Y.-F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti- inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Asses 2008; 12(11): 1-278.</p><p>Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998; 37: 937-45.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.</p><p>Altman R.D. The classification of osteoarthritis. J Rheumatol 1995; (Suppl.)43: 42-3.</p><p>Каратеев А.Е., Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.: Анко, 2000; 142 с.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009; 168 с.</p><p>Елисеев М.С., Барскова В.Г., Владимиров С.А. Применение инъекционной формы мелоксикама (Амелотекс) у больных гонартрозом. Совр ревматол. 2009; 3: 53-6.</p><p>Peura D.A. Prevention of nonsteroidal anti- inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004; 117(Suppl. 5A): S63-S71.</p><p>Цветкова Е.С., Панасюк Е.Ю., Рубцов О.В. Новые возможности применения мовалиса при ревматических заболеваниях. Науч.- практич. ревматол. 2003; 4: 45-67.</p><p>Tuerck D., Roth W., Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35(Suppl. 1): 13-6.</p><p>Davies N.M., Skjodt N.M. Clinical pharmacokinetics of meloxicam: a cyclooxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 1999; 36: 115-26.</p></div><br />
Рецензия
Для цитирования:
Eliseev MS, Владимиров СА, Eliseyev MS, Владимиров СА. Применение мелоксикама (амелотекс®) у больных гонартрозом. Современная ревматология. 2011;5(2):31-34. https://doi.org/10.14412/1996-7012-2011-665
For citation:
Eliseev MS, Vladimirov SA, Eliseyev MS, Vladimirov SA. Use of meloxicam (amelotex®) in patients with gonarthrosis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2011;5(2):31-34. https://doi.org/10.14412/1996-7012-2011-665
Послать статью по эл. почте 